ZYME
Zymeworks Inc. · Healthcare · Market cap $1.8B
Insiders sold $1.8M net in the last 90 days ·3 sellers, 0 buyers· latest Form 4 filed Nov 18, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$6.4M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Latest filing
Nov 18, 2026
Platshon Scott
Zymeworks Inc. (ZYME) has 13 SEC Form 4 filings (30 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Nov 18, 2026.
Inside the rolling window, 6 insiders at Zymeworks Inc. reported no open-market purchases and 11 open-market sales totaling $6.4M. The most active filer is Chief Scientific Officer Moore Paul Andrew with 3 filings. Insiders have net sold $1.8M over the trailing 6 months. The most recent open-market filing is a sale of 15,292 shares by EVP, Chief Business Officer Platshon Scott, dated Nov 18, 2026, worth $382K.
- Industry:Biotechnology
- CEO:Kenneth H. Galbraith
- Employees:231
- HQ:Middletown, DE, US
- IPO:2017-04-28
| Source | |||||||
|---|---|---|---|---|---|---|---|
Platshon ScottFirst filing | EVP, Chief Business Officer | Sale | 15,292 | $382K | Nov 18 | +0.4% | SEC ↗ |
Moore Paul AndrewFirst in 10 months | Chief Scientific Officer | Sale | 39,741 | $1.0M | Nov 16 | -1.2% | SEC ↗ |
Schayowitz AdamFirst filing | EVP, Head of R&D | Sale | 13,832 | $358K | Oct 9 | +1.4% | SEC ↗ |
Hollywood MarkFirst filing | EVP & Chief Operating Officer | Sale | 6,120 | $139K | Jan 13 | +9.3% | SEC ↗ |
| Chief Scientific Officer | Sale | 9,560 | $217K | Jan 12 | +12.9% | SEC ↗ | |
| Chair & CEO | Sale | 30,424 | $690K | Jan 12 | +12.9% | SEC ↗ | |
| EVP & Chief Medical Officer | Sale | 9,310 | $211K | Jan 12 | +12.9% | SEC ↗ | |
| Chair & CEO | Sale | 54,343 | $1.4M | Jan 5 | +2.6% | SEC ↗ | |
Moore Paul AndrewFirst filing | Chief Scientific Officer | Sale | 20,110 | $505K | Jan 5 | — | SEC ↗ |
Smith Jeffrey T LFirst filing | EVP & Chief Medical Officer | Sale | 10,538 | $264K | Jan 5 | — | SEC ↗ |
Galbraith KennethFirst filing | Chair & CEO | Sale | 47,528 | $1.3M | Dec 22 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does ZYME have?
Zymeworks Inc. (ZYME) has 13 SEC Form 4 filings (30 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Nov 18, 2026.
When was the most recent SEC Form 4 filing for ZYME?
The most recent Form 4 filing for ZYME on Tracefour is dated Nov 18, 2026.
Who is the most active insider at ZYME?
The most active SEC Form 4 filer at ZYME in the rolling window is Chief Scientific Officer Moore Paul Andrew, with 3 filings.
What is the net insider flow at ZYME over the last 6 months?
Over the trailing 180 days, insiders at ZYME have net sold $1.8M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ZYME in the current window?
Inside the rolling window, insiders at ZYME bought $0 and sold $6.4M based on SEC Form 4 filings.
Can I get alerts for ZYME insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Zymeworks Inc. (ZYME). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Zymeworks Inc. is in the Healthcare sector.